Nothing Special   »   [go: up one dir, main page]

WO2006108414A2 - Agent for use in the therapy and prophylaxis of skin diseases - Google Patents

Agent for use in the therapy and prophylaxis of skin diseases Download PDF

Info

Publication number
WO2006108414A2
WO2006108414A2 PCT/DE2006/000700 DE2006000700W WO2006108414A2 WO 2006108414 A2 WO2006108414 A2 WO 2006108414A2 DE 2006000700 W DE2006000700 W DE 2006000700W WO 2006108414 A2 WO2006108414 A2 WO 2006108414A2
Authority
WO
WIPO (PCT)
Prior art keywords
zeolite
composition according
psoriasis
calcium
agent
Prior art date
Application number
PCT/DE2006/000700
Other languages
German (de)
French (fr)
Other versions
WO2006108414A3 (en
Inventor
Jörg Schulz
Slavko Ivkovic
Tihomir Lelas
Peter Bendzko
Original Assignee
Klinomed Institut für angewandte Nanotechnologie und Nanomedizin GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinomed Institut für angewandte Nanotechnologie und Nanomedizin GmbH filed Critical Klinomed Institut für angewandte Nanotechnologie und Nanomedizin GmbH
Publication of WO2006108414A2 publication Critical patent/WO2006108414A2/en
Publication of WO2006108414A3 publication Critical patent/WO2006108414A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams

Definitions

  • the invention relates to an agent for the therapy and prophylaxis of skin diseases, in particular psoriasis, neurodermatitis or atopic dermatitis and acne. Areas of application of the invention are the medicine and the food industry.
  • Psoriasis vulgaris is one of the most widespread diseases in industrialized countries. Psoriasis is a chronic, inflammatory disease of the skin and sometimes of the joints. It affects between one and three percent of the population and is thus one of the most common skin diseases.
  • Psoriasis is not an infectious disease and does not lead to an involvement of internal organs. But there is a genetic predisposition (genetic disposition).
  • Signs of psoriasis vulgaris are the typical skin changes. These are sharply demarcated reddish, slightly raised disease centers, which are covered by more or less dense silvery-white scales.
  • the size of the herd can vary widely from small pointy flocks to several palm-sized skin areas (plaques).
  • the superficial scales can be easily detached, the deeper ones, however, are stronger and can finally be considered as remove coherent, sheet-like cuticle. As a result, small, punctate skin bleeding occurs.
  • Psoriasis vulgaris can occur acutely, with numerous, drop to coin-sized psoriasis herds throughout the body.
  • psoriasis runs in batches, psoriasis can occur again and again after healing with therapy, or it can come in bursts to a worsening of psoriasis.
  • Various types of light therapy e.g., systemic PUVA therapy
  • systemic PUVA therapy e.g., systemic PUVA therapy
  • Systemic therapy options e.g., acitretin, methotrexate, cyclosporin A
  • psoriasis is currently not curable. Relapses of illness occur for life. In some patients, the disease is progressively progressive, with more and more skin involvement, while about two-thirds of psoriasis patients repeatedly experience periods when the disease does not appear.
  • the aim of the invention is to find new ways to treat skin diseases.
  • the invention has for its object to develop new means by which inflammatory skin diseases, especially psoriasis can be treated.
  • the Kemgedanke of the invention is to provide a means of zeolites and nettle extracts or calcium and / or magnesium salts for the treatment and prophylaxis of inflammatory skin diseases available.
  • the components of nettle extracts or calcium and / or magnesium salts can be used alone or as a mixture in a quantitative ratio of 1 to 99% to 99 to 1%.
  • Zeolites are natural minerals of volcanic origin, a total of over 20 natural species are known. The most interesting of the present invention are heulandite (also called clinoptilolite), natrolite and thomsonite. Physicochemically, zeolites can be characterized as crystalline hydrated alumino-silicates of alkali and alkaline-earth ions. Their ability to reversibly absorb and release water as well as exchange cations in the interstices makes it possible to use them as "molecular sieves".
  • zeolite preferably heulandite / clinoptilolite, having a particle size of less than 100 ⁇ m, preferably less than 5 ⁇ m, is used to prepare the agent according to the invention.
  • the starting material for the production of the second component nettle extract is the entire plant, preferably the leaves of the nettle. Both fresh nettles or nettle leaves and dried, in particular freeze-dried nettles or nettle leaves can be used.
  • the extraction of the fresh plant or its leaves is preferably carried out after freezing the plant or its leaves, for example in liquid nitrogen.
  • the nettles or nettle leaves are ground and extracted per kg with 5 l extractant. Extractants are water, ethanol, propanol or isopropanol or mixtures thereof.
  • the extraction can be carried out at temperatures between 10 and 7O 0 C, preferably the extraction is at room temperature.
  • the actual extraction process is straightforward and can be done in a conventional manner and using equipment known per se, for example by maceration or percolation.
  • the duration of the extraction depends on several factors (extractant, temperature, degree of comminution, type of extractor, etc.).
  • the end of the extraction process in a one-step process is achieved if the solids content of the extract remains constant, or in multi-step processes, when the solids content of the extract goes to zero. As a rule, the extraction takes between 12 and 72 hours.
  • the zeolite and nettle extract composition according to the invention is prepared by incubation of the zeolites in the nettle extract, which can optionally be diluted with extractant for this purpose.
  • the incubation is carried out with constant stirring and can take place at temperatures between 1 and 7O 0 C, preferably, the incubation at room temperature.
  • the duration of the incubation depends on the grain size of the zeolites. At a particle size of 50 microns saturation of the zeolites with the extract takes place within 3 hours, with a particle size of 5 microns within an hour.
  • the saturated with nettle extract zeolites may by suitable methods such as freeze drying or heating to 25 - 6O 0 C, preferably at 35-40 0 C to be dried.
  • the second component calcium and / or magnesium salts preferably consists of the corresponding carbonates, sulfates or chlorides.
  • the exact composition of the salts is variable.
  • dolomite is a natural calcium and magnesium carbonate used. The composition of this mineral varies depending on the place of origin. For example, Jurassic dolomite consists of 55% calcium carbonate and 43% magnesium carbonate, whereas Semmering's dolomite consists of 4% calcium carbonate and 90% magnesium carbonate.
  • the invention 'means using calcium and / or magnesium salts can be prepared in two different ways.
  • the first possibility is to incubate the zeolites with saturated solutions of the salts.
  • the incubation is carried out with constant stirring and can take place at temperatures between 1 and 7O 0 C, preferably, the incubation at room temperature.
  • the duration of the incubation depends on the grain size of the zeolites. With a grain size of 50 microns saturation of the zeolites with the extract takes place within 3 hours, with a grain size of 5 microns within one hour.
  • the saturated with the calcium and / or magnesium salts zeolites may by suitable methods such as freeze drying or heating to 25-90 0 C, preferably at 35 - 4O 0 C to be dried.
  • the second manufacturing method of the agent using calcium and / or magnesium salts is to pulverize these salts and to intimately mix with the zeolites according to the usual methods. This can be done for example in a mill. The mixing process is completed as soon as a homogeneous mixture is formed, which is usually the case after about 30 minutes.
  • the agent according to the invention is particularly suitable for the therapy and prophylaxis of special forms of psoriasis such as psoriasis of the palms and soles, nail psoriasis, erythrodermatic form of psoriasis, psoriasis pustulosa or psoriasis arthropathica, which are particularly resistant to treatment in the prior art.
  • special forms of psoriasis such as psoriasis of the palms and soles, nail psoriasis, erythrodermatic form of psoriasis, psoriasis pustulosa or psoriasis arthropathica, which are particularly resistant to treatment in the prior art.
  • zeolites one or more zeolite types heulandite / clinoptilolite, natrolite and thomsonite can be used.
  • micronized heulandite / clinoptilolite having a particle diameter of less than 5 ⁇ m is used.
  • the nettle extract is made from stinging nettles of the genus Urtica dioica (Great nettle) and / or Urtica urens (Small stinging nettle).
  • the corresponding carbonates, sulfates and / or chlorides can be used.
  • the natural mineral dolomite is used.
  • the agent according to the invention may also contain plant immunomodulators as further substances.
  • the zeolite content is between 1% and 95% with a proportion of the nettle extract or the calcium and / or magnesium salts of 5% to 80%.
  • the proportions for zeolite are 40-80% and for the nettle extract or the calcium and / or magnesium salts 20-60%.
  • Particularly suitable is an agent with a proportion of zeolite of 50-80% and a content of nettle extract or the calcium and / or magnesium salts of 1-20%.
  • the agent according to the invention can be administered in the form of a dietary supplement.
  • the treatment can be assisted by the use of 100% zeolite powder and / or zeolite-containing lotion and / or bathing in zeolite-containing bath salt.
  • the administration of the agent may be by oral ingestion and / or by application to the skin, for which purpose the agent may be in the form of powders, tablets, capsules, cream, milk, gel, emulsion, soap, shampoo or in aqueous form.
  • zeolite and nettle extract or calcium and / or magnesium salts leads to an unexpected increase in the therapeutic effect, as a study on psoriasis patients made clear.
  • 5 - 2g of the agent according to the invention with a ratio of 75% zeolite to 25% nettle extract resulted in a normalization of up to 50% of the affected skin areas.
  • normalization can be achieved up to 100%.
  • a total of 20 patients with confirmed psoriasis vulgaris were evaluated at a dermatological practice in Crivitz and subjected to a 12-week treatment with 3 x 2 capsules Megamin forte a 500 mg daily.
  • Megamin forte capsules contain 75% micronized heulandite / clinoptilolite with a particle diameter of less than 5 ⁇ m (EP1316530) and 25% nettle extract or powdered dolomite or a mixture of these two components.
  • the extract was made by maceration from leaves of stinging nettle Urtica dioica prepared by extraction with isopropanol at room temperature for 24 hours.
  • a total of 20 patients with confirmed psoriasis vulgaris were evaluated at a dermatological practice in Crivitz and subjected to a 12-week treatment with 3 x 2 Megamin forte a 500 mg capsules daily.
  • twice daily the topical application of the affected skin areas with zeolite powder and zeolite-containing ointment and 1-2 times a week a bath with zeolite-containing bath salts.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to an agent for use in the therapy and prophylaxis of skin diseases, especially psoriasis, neurodermitis or atopic dermatitis. The invention is characterized in that the agent comprises zeolites and stinging nettle leaf extracts or calcium and/or magnesium salts. The inventive agent can be orally administered and/or applied topically to the skin.

Description

Mittel zur Therapie und Prophylaxe von HauterkrankungenAgent for the therapy and prophylaxis of skin diseases
Beschreibungdescription
Die Erfindung betrifft ein Mittel zur Therapie und Prophylaxe von Hauterkrankungen, insbesondere von Psoriasis, Neurodermitis oder atopischer Dermatitis sowie Akne. Anwendungsgebiete der Erfindung sind die Medizin und die Nahrungsmittelindustrie.The invention relates to an agent for the therapy and prophylaxis of skin diseases, in particular psoriasis, neurodermatitis or atopic dermatitis and acne. Areas of application of the invention are the medicine and the food industry.
Eine der am weitverbreitetsten Krankheiten in den Industrieländern ist die Schuppenflechte Psoriasis vulgaris. Die Psoriasis ist eine chronische, entzündliche Erkrankung der Haut und teilweise auch der Gelenke. Sie betrifft zwischen ein und drei Prozent der Bevölkerung und ist somit eine der häufigsten Hauterkrankungen.Psoriasis vulgaris is one of the most widespread diseases in industrialized countries. Psoriasis is a chronic, inflammatory disease of the skin and sometimes of the joints. It affects between one and three percent of the population and is thus one of the most common skin diseases.
Die Psoriasis ist keine ansteckende Erkrankung und führt auch nicht zu einer Beteiligung innerer Organe. Es liegt aber eine genetische Veranlagung (genetische Disposition) vor.Psoriasis is not an infectious disease and does not lead to an involvement of internal organs. But there is a genetic predisposition (genetic disposition).
Trotz Kenntnis zahlreicher Details über die Psoriasis ist die genaue Entstehung und Ursache der Erkrankung derzeit noch nicht bekannt. Eine genetische Veränderung gilt als sicher, der genaue Erbgang ist allerdings ungeklärt. Forschungsergebnisse der letzten Jahre weisen auf eine bedeutende Rolle des Immunsystems in der Entstehung der Erkrankung hin, die Psoriasis wird heute als Autoimmunerkrankung angesehen.Despite knowledge of many details about psoriasis, the exact origin and cause of the disease is currently unknown. A genetic change is considered safe, but the exact inheritance is unclear. Research results of recent years indicate a significant role of the immune system in the development of the disease, psoriasis is now considered an autoimmune disease.
Zeichen der Psoriasis vulgaris sind die typischen Hautveränderungen. Diese sind scharf begrenzte rötliche, leicht erhabene Krankheitsherde, die von mehr oder minder dichten silbrig-weißen Schuppen bedeckt sind. Die Größe der Herde kann stark variieren von kleinen punktförmigen Herden bis zu mehreren handtellergroßen Hautbezirken (Plaques). Die oberflächlichen Schuppen lassen sich leicht ablösen, die tieferen sitzen dagegen fester und lassen sich schlussendlich als zusammenhängendes, blattförmiges Häutchen entfernen. In der Folge treten kleine, punktförmige Hautblutungen auf.Signs of psoriasis vulgaris are the typical skin changes. These are sharply demarcated reddish, slightly raised disease centers, which are covered by more or less dense silvery-white scales. The size of the herd can vary widely from small pointy flocks to several palm-sized skin areas (plaques). The superficial scales can be easily detached, the deeper ones, however, are stronger and can finally be considered as remove coherent, sheet-like cuticle. As a result, small, punctate skin bleeding occurs.
Die Psoriasis vulgaris kann akut auftreten, mit zahlreichen, tropfen- bis münzgroßen Psoriasis-Herden am gesamten Körper.Psoriasis vulgaris can occur acutely, with numerous, drop to coin-sized psoriasis herds throughout the body.
Die Sonderformen der Psoriasis unterscheiden sich oft sehr deutlich im klinischen Bild und sind mitunter sehr therapieresistent.The special forms of psoriasis often differ very clearly in the clinical picture and are sometimes very resistant to therapy.
Dabei wird unterschieden inIt is distinguished in
• Psoriasis der Handflächen und Fußsohle• Psoriasis of the palms and sole
• Nagel-Psoriasis• nail psoriasis
• erythrodermatische Form der Psoriasis• erythrodermatic form of psoriasis
• Psoriasis pustulosa• psoriasis pustulosa
• Psoriasis arthropathica• psoriasis arthropathica
Die Schuppenflechte verläuft schubweise, Psoriasisherde können auch nach Abheilung unter Therapie immer wieder neu auftreten, oder es kann schubweise zu einer Verschlechterung der Psoriasis kommen.The psoriasis runs in batches, psoriasis can occur again and again after healing with therapy, or it can come in bursts to a worsening of psoriasis.
Je nach Schweregrad und klinischer Ausprägung stehen bisher verschiedene Behandlungsmöglichkeiten zur Verfügung:Depending on the severity and clinical manifestation, different treatment options are available:
• lokale Behandlungsmaßnahmen (z.B. rückfettende Ölbäder, Duschöle, Fettsalben oder fette Cremes)Local treatments (e.g., moisturizing oil baths, shower oils, greasy ointments or oily creams)
• verschiedene Arten der Lichttherapie (z.B. systemische PUVA-Therapie)Various types of light therapy (e.g., systemic PUVA therapy)
• systemische Therapiemöglichkeiten (z.B. Acitretin, Methotrexat, CyclosporinA)Systemic therapy options (e.g., acitretin, methotrexate, cyclosporin A)
Allgemeine Maßnahmen, wie ausgewogene Ernährung, Vermeiden von Alkohol und Nikotin sowie eine geregelte Lebensweise sollen Bestandteil jeder Psoriasis- Behandlung sein. Eine Klimatherapie - d. h. die Kombination aus Baden im Toten Meer (hypertone Salzlösung) und zunehmender Sonnenbestrahlung führt oft zu einer deutlichen Besserung.General measures such as balanced nutrition, avoidance of alcohol and nicotine as well as a regulated way of life should be part of every psoriasis treatment. Climatotherapy - ie the combination of bathing in the dead Sea (hypertonic saline) and increasing sunshine often leads to a significant improvement.
Trotz der bisherigen Behandlungsmethoden ist Psoriasis derzeit nicht heilbar. Krankheitsschübe treten lebenslang auf. Bei einem Teil der Patienten verläuft die Erkrankung kontinuierlich fortschreitend, mit immer ausgedehnterem Hautbefall, während etwa zwei Drittel der Psoriasis-Patienten immer wieder Zeiten erleben, in der die Krankheit nicht in Erscheinung tritt.Despite previous treatment methods, psoriasis is currently not curable. Relapses of illness occur for life. In some patients, the disease is progressively progressive, with more and more skin involvement, while about two-thirds of psoriasis patients repeatedly experience periods when the disease does not appear.
Ziel der Erfindung ist es, neue Möglichkeiten zur Behandlung von Hauterkrankungen zu finden. Der Erfindung liegt die Aufgabe zugrunde, neue Mittel zu entwickeln, mit denen entzündliche Hauterkrankungen, insbesondere Psoriasis behandelt werden können.The aim of the invention is to find new ways to treat skin diseases. The invention has for its object to develop new means by which inflammatory skin diseases, especially psoriasis can be treated.
Die Erfindung wird gemäß Anspruch 1 und 17 realisiert, die Unteransprüche sind Vorzugsvarianten. Der Kemgedanke der Erfindung besteht darin, ein Mittel aus Zeolithen und Brennnesselextrakten bzw. Calcium- und/oder Magnesiumsalzen zur Therapie und Prophylaxe entzündlicher Hauterkrankungen zur Verfügung zu stellen.The invention is realized according to claim 1 and 17, the dependent claims are preferred variants. The Kemgedanke of the invention is to provide a means of zeolites and nettle extracts or calcium and / or magnesium salts for the treatment and prophylaxis of inflammatory skin diseases available.
Dabei können die Komponenten Brennnesselextrakte bzw. Calcium- und/oder Magnesiumsalze allein oder als Gemisch im Mengenverhältnis von 1 - 99 % bis 99 - 1 % eingesetzt werden.The components of nettle extracts or calcium and / or magnesium salts can be used alone or as a mixture in a quantitative ratio of 1 to 99% to 99 to 1%.
Zeolithe sind natürliche Mineralien vulkanischen Ursprungs, insgesamt sind über 20 natürliche Arten bekannt. Die erfindungsgemäß interessantesten stellen Heulandit (auch Klinoptilolith genannt), Natrolith und Thomsonit dar. Physikochemisch lassen sich Zeolithe als kristalline hydratisierte Aluminsilikate von Alkali- und Erdalkali-Ionen charakterisieren. Ihre Fähigkeit reversibel Wasser aufzunehmen und wieder abzugeben sowie Kationen in den Zwischenräumen auszutauschen, macht es möglich sie als „Molekularsieb" zu verwenden.Zeolites are natural minerals of volcanic origin, a total of over 20 natural species are known. The most interesting of the present invention are heulandite (also called clinoptilolite), natrolite and thomsonite. Physicochemically, zeolites can be characterized as crystalline hydrated alumino-silicates of alkali and alkaline-earth ions. Their ability to reversibly absorb and release water as well as exchange cations in the interstices makes it possible to use them as "molecular sieves".
Für die Anwendung bei Tier und Mensch ist es wichtig anzumerken, dass systemisch aufgenommene Zeolithe inert sind, d. h. sie reagieren in keiner Weise chemisch mit Nahrungsbestandteilen oder Körperflüssigkeiten. Ihre Wirkungen beruhen einzig auf physikalischen Kräften, weshalb auch zu erwartende Nebenwirkungen unbedeutend sind.For animal and human applications, it is important to note that systemically incorporated zeolites are inert, that is, they do not react chemically with dietary or bodily fluids. Their effects are based solely on physical forces, which is why expected side effects are insignificant.
Erfindungsgemäß wird mechanisch zerkleinertes Zeolith verwendet, dass in unterschiedlichen Korngrößen im Handel erwerbbar ist. Zur Herstellung des erfindungsgemäßen Mittels wird Zeolith, bevorzugt Heulandit/klinoptilolith, mit Korngrößer kleiner als 100 μm, vorzugsweise kleiner als 5 μm verwendet.According to the invention, mechanically comminuted zeolite is used, which can be obtained commercially in different particle sizes. Zeolite, preferably heulandite / clinoptilolite, having a particle size of less than 100 μm, preferably less than 5 μm, is used to prepare the agent according to the invention.
Als Ausgangsstoff für die Herstellung der zweiten Komponente Brennnesselextrakt dient die gesamte Pflanze, bevorzugt die Blätter der Brennnessel. Es können sowohl frische Brennnesseln bzw. Brennnesselblätter als auch getrocknete, insbesondere gefriergetrocknete Brennnesseln bzw. Brennnesselblätter verwendet werden. Die Extraktion der frischen Pflanze bzw. ihrer Blätter erfolgt vorzugsweise nach Einfrieren der Pflanze bzw. ihrer Blätter, beispielsweise in flüssigem Stickstoff. Die Brennnessel bzw. Brennnesselblätter werden vermählen und pro kg mit 5 I Extraktionsmittel ausgezogen. Extraktionsmittel sind Wasser, Ethanol, Propanol bzw. Isopropanol oder deren Gemische. Die Extraktion kann bei Temperaturen zwischen 10 und 7O0C durchgeführt werden, bevorzugt ist die Extraktion bei Raumtemperatur. Der eigentliche Extraktionsvorgang ist unproblematisch und kann in an sich bekannter Weise und unter Verwendung an sich bekannter Apparaturen z.B. durch Mazeration oder Perkolation erfolgen. Die Dauer der Extraktion hängt von mehreren Faktoren ab (Extraktionsmittel, Temperatur, Zerkleinerungsgrad, Art des Extraktors usw.). Das Ende des Extraktionsvorgangs bei einem einstufigem Verfahren ist erreicht, wenn der Feststoffgehalt des Extraktes konstant bleibt, bzw. in mehrstufigen Verfahren, wenn der Feststoffgehalt des Extraktes gegen 0 geht. In der Regel dauert die Extraktion zwischen 12 und 72 Stunden.The starting material for the production of the second component nettle extract is the entire plant, preferably the leaves of the nettle. Both fresh nettles or nettle leaves and dried, in particular freeze-dried nettles or nettle leaves can be used. The extraction of the fresh plant or its leaves is preferably carried out after freezing the plant or its leaves, for example in liquid nitrogen. The nettles or nettle leaves are ground and extracted per kg with 5 l extractant. Extractants are water, ethanol, propanol or isopropanol or mixtures thereof. The extraction can be carried out at temperatures between 10 and 7O 0 C, preferably the extraction is at room temperature. The actual extraction process is straightforward and can be done in a conventional manner and using equipment known per se, for example by maceration or percolation. The duration of the extraction depends on several factors (extractant, temperature, degree of comminution, type of extractor, etc.). The end of the extraction process in a one-step process is achieved if the solids content of the extract remains constant, or in multi-step processes, when the solids content of the extract goes to zero. As a rule, the extraction takes between 12 and 72 hours.
Das erfindungsgemäße Mittel aus Zeolith und Brennnesselextrakt wird hergestellt durch Inkubation der Zeolithe im Brennnesselextrakt, der hierzu gegebenenfalls mit Extraktionsmittel verdünnt werden kann. Die Inkubation erfolgt unter konstantem Rühren und kann bei Temperaturen zwischen 1 und 7O0C stattfinden, bevorzugt ist die Inkubation bei Raumtemperatur. Die Dauer der Inkubation richtet sich nach der Korngröße der Zeolithe. Bei einer Korngröße von 50 μm erfolgt eine Sättigung der Zeolithe mit dem Extrakt innerhalb von 3 Stunden, bei einer Korngröße von 5 μm innerhalb von einer Stunde. Die mit Brennnesselextrakt gesättigten Zeolithe können mit geeigneten Methoden wie Gefriertrocknung oder Erwärmung auf 25 - 6O0C, vorzugsweise bei 35 - 400C getrocknet werden.The zeolite and nettle extract composition according to the invention is prepared by incubation of the zeolites in the nettle extract, which can optionally be diluted with extractant for this purpose. The incubation is carried out with constant stirring and can take place at temperatures between 1 and 7O 0 C, preferably, the incubation at room temperature. The duration of the incubation depends on the grain size of the zeolites. At a particle size of 50 microns saturation of the zeolites with the extract takes place within 3 hours, with a particle size of 5 microns within an hour. The saturated with nettle extract zeolites may by suitable methods such as freeze drying or heating to 25 - 6O 0 C, preferably at 35-40 0 C to be dried.
Die zweite Komponente Calcium- und/oder Magnesiumsalze besteht bevorzugt aus den entsprechenden Carbonaten, Sulfaten oder Chloriden. Die genaue Zusammensetzung der Salze ist variabel. In einer besonders bevorzugten Variante der Erfindung wird Dolomit ein natürliches Calcium- und Magnesiumcarbonat eingesetzt. Die Zusammensetzung dieses Minerals unterliegt je nach Herkunftsort gewissen Schwankungen. So besteht beispielsweise jurassischer Dolomit aus 55 % Calciumcarbonat und aus 43 % Magnesiumcarbonat, der Dolomit von Semmering hingegen aus 4 % Calciumcarbonat und aus 90 % Magnesiumcarbonat.The second component calcium and / or magnesium salts preferably consists of the corresponding carbonates, sulfates or chlorides. The exact composition of the salts is variable. In a particularly preferred variant of the invention dolomite is a natural calcium and magnesium carbonate used. The composition of this mineral varies depending on the place of origin. For example, Jurassic dolomite consists of 55% calcium carbonate and 43% magnesium carbonate, whereas Semmering's dolomite consists of 4% calcium carbonate and 90% magnesium carbonate.
Das erfindungsgemäße 'Mittel unter Verwendung von Calcium- und/oder Magnesiumsalzen kann auf zwei verschiedene Weisen hergestellt werden. Die erste Möglichkeit besteht in einer Inkubation der Zeolithe mit gesättigten Lösungen der Salze. Die Inkubation erfolgt unter konstantem Rühren und kann bei Temperaturen zwischen 1 und 7O0C stattfinden, bevorzugt ist die Inkubation bei Raumtemperatur. Die Dauer der Inkubation richtet sich nach der Korngröße der Zeolithe. Bei einer Korngröße von 50 μm erfolgt eine Sättigung der Zeolithe mit dem Extrakt innerhalb von 3 Stunden, bei einer Korngröße von 5 μm innerhalb von einer Stunde. Die mit den Calcium- und/oder Magnesiumsalzen gesättigten Zeolithe können mit geeigneten Methoden wie Gefriertrocknung oder Erwärmung auf 25 - 900C, vorzugsweise bei 35 - 4O0C getrocknet werden.The invention 'means using calcium and / or magnesium salts can be prepared in two different ways. The first possibility is to incubate the zeolites with saturated solutions of the salts. The incubation is carried out with constant stirring and can take place at temperatures between 1 and 7O 0 C, preferably, the incubation at room temperature. The duration of the incubation depends on the grain size of the zeolites. With a grain size of 50 microns saturation of the zeolites with the extract takes place within 3 hours, with a grain size of 5 microns within one hour. The saturated with the calcium and / or magnesium salts zeolites may by suitable methods such as freeze drying or heating to 25-90 0 C, preferably at 35 - 4O 0 C to be dried.
Das zweite Herstellungsverfahren des Mittels unter Verwendung von Calcium- und/oder Magnesiumsalzen besteht darin, diese Salze zu pulverisieren und mit den Zeolithen nach den üblichen Verfahren innig zu vermengen. Dies kann beispielsweise in einer Mühle erfolgen. Der Mischungsprozess ist beendet, sobald ein homogenes Gemenge entstanden ist, in der Regel ist das nach ca. 30 Minuten der Fall.The second manufacturing method of the agent using calcium and / or magnesium salts is to pulverize these salts and to intimately mix with the zeolites according to the usual methods. This can be done for example in a mill. The mixing process is completed as soon as a homogeneous mixture is formed, which is usually the case after about 30 minutes.
Gemäß der Erfindung wird ein neues Mittel aus Zeolithen und Brennnesselextrakt bzw. Calcium- und/oder Magnesiumsalzen sowie gegebenenfalls aus weiteren Stoffen zur Verfügung gestellt, das zur Therapie von Hauterkrankung, insbesondere Psoriasis, Neurodermitis, Akne bzw. atopischer Dermatitis, führt und auch der Prophylaxe dieser Krankheiten dienen kann.According to the invention, a new agent of zeolites and nettle extract or calcium and / or magnesium salts and optionally from further Materials provided for the treatment of skin disease, especially psoriasis, atopic dermatitis, acne or atopic dermatitis, leads and can also serve the prophylaxis of these diseases.
Das erfindungsgemäße Mittel ist insbesondere zur Therapie und Prophylaxe von Sonderformen der Psoriasis wie Psoriasis der Handflächen und Fußsohlen, Nagel- Psoriasis, erythrodermatische Form der Psoriasis, Psoriasis pustulosa oder Psoriasis arthropathica geeignet, die nach dem bisherigen Stand der Technik besonders therapieresistent sind.The agent according to the invention is particularly suitable for the therapy and prophylaxis of special forms of psoriasis such as psoriasis of the palms and soles, nail psoriasis, erythrodermatic form of psoriasis, psoriasis pustulosa or psoriasis arthropathica, which are particularly resistant to treatment in the prior art.
Als Zeolithe können eine oder mehrere der Zeolitharten Heulandit/Klinoptilolith, Natrolith und Thomsonit verwendet werden. In einer Vorzugsvariante wird mikronisiertes Heulandit/Klinoptilolith mit einem Teilchendurchmesser von weniger als 5 μm eingesetzt.As zeolites one or more zeolite types heulandite / clinoptilolite, natrolite and thomsonite can be used. In a preferred variant, micronized heulandite / clinoptilolite having a particle diameter of less than 5 μm is used.
Der Brennnesselextrakt wird aus Brennnesseln der Gattung Urtica dioica (Große Brennnessel) und/oder Urtica urens (kleine Brennnessel) hergestellt.The nettle extract is made from stinging nettles of the genus Urtica dioica (Great nettle) and / or Urtica urens (Small stinging nettle).
Als Calcium- und/oder Magnesiumsalze können die entsprechenden Carbonate, Sulfate und/oder Chloride verwendet werden. In einer bevorzugten Variante wird das natürliche Mineral Dolomit eingesetzt.As calcium and / or magnesium salts, the corresponding carbonates, sulfates and / or chlorides can be used. In a preferred variant, the natural mineral dolomite is used.
In einer Vorzugsvariante kann das erfindungsgemäße Mittel noch pflanzliche Immunmodulatoren als weitere Stoffe enthalten.In a preferred variant, the agent according to the invention may also contain plant immunomodulators as further substances.
Der Zeolithanteil beträgt zwischen 1 % und 95 % bei einem Anteil des Brennnesselextrakts bzw. der Calcium- und/oder Magnesiumsalze von 5 % bis 80 %. In einer Vorzugsvariante betragen die Anteile für Zeolith 40 - 80 % und für den Brennnesselextrakt bzw. der Calcium- und/oder Magnesiumsalze 20 - 60 %. Besonders geeignet ist ein Mittel mit einen Anteil an Zeolith von 50 - 80 % und einen Anteil an Brennnesselextrakt bzw. der Calcium- und/oder Magnesiumsalze von 1- 20%. Das erfindungsgemäße Mittel kann in Form eines Nahrungsergänzungsmittels verabreicht werden. Gleichzeitig kann die Behandlung durch die Anwendung von 100%igem Zeolith-Puder und/oder Zeolith-haltiger Lotion und/oder durch Baden in Zeolith-haltigem Badesalz unterstützt werden.The zeolite content is between 1% and 95% with a proportion of the nettle extract or the calcium and / or magnesium salts of 5% to 80%. In a preferred variant, the proportions for zeolite are 40-80% and for the nettle extract or the calcium and / or magnesium salts 20-60%. Particularly suitable is an agent with a proportion of zeolite of 50-80% and a content of nettle extract or the calcium and / or magnesium salts of 1-20%. The agent according to the invention can be administered in the form of a dietary supplement. At the same time, the treatment can be assisted by the use of 100% zeolite powder and / or zeolite-containing lotion and / or bathing in zeolite-containing bath salt.
Die Verabreichung des Mittels kann durch orale Einnahme und/oder durch Auftragen auf die Haut erfolgen, hierzu kann das Mittel in Form von Pulvern, Tabletten, Kapseln, Creme, Milch, Gel, Emulsion, Seife, Shampoo oder in wässriger Form vorliegen.The administration of the agent may be by oral ingestion and / or by application to the skin, for which purpose the agent may be in the form of powders, tablets, capsules, cream, milk, gel, emulsion, soap, shampoo or in aqueous form.
Abschließend ist festzustellen, dass die Behandlung von Hautkrankheiten, insbesondere Psoriasis vulgaris, Neurodermitis und atopische Dermatitis sowie Akne mit dem erfindungsgemäßen Mittel erstaunliche Heilungserfolge zeigt.In conclusion, it should be noted that the treatment of skin diseases, in particular psoriasis vulgaris, atopic dermatitis and atopic dermatitis as well as acne with the agent according to the invention shows astonishing healing results.
Die neuartige Kombination Zeolith und Brennnesselextrakt bzw. Calcium- und/oder Magnesiumsalze führt zu einer unerwarteten Steigerung des therapeutischen Effekts, wie eine Studie an Psoriasis-Patienten deutlich machte. Bereits nach wenigen Wochen peroraler Einnahme von täglich 1 ,5 - 2g des erfindungsgemäßen Mittels mit einem Verhältnis von 75% Zeolith zu 25% Brennnesselextrakt führte zu einer Normalisierung von bis 50% der befallenen Hautareale. Bei einer zusätzlichen Applikation von Zeolith-Puder bzw. Behandlung mit Zeolith-haltiger Salbe oder Badezusätzen kann eine Normalisierung bis zu 100 % erreicht werden.The novel combination of zeolite and nettle extract or calcium and / or magnesium salts leads to an unexpected increase in the therapeutic effect, as a study on psoriasis patients made clear. After only a few weeks peroral intake of daily 1, 5 - 2g of the agent according to the invention with a ratio of 75% zeolite to 25% nettle extract resulted in a normalization of up to 50% of the affected skin areas. In an additional application of zeolite powder or treatment with zeolite-containing ointment or bath additives normalization can be achieved up to 100%.
Die Erfindung soll nachfolgend durch Anwendungsbeispiele näher erläutert werden:The invention will be explained in more detail below by application examples:
Anwendungsbeispiel 1Application example 1
Es wurden insgesamt 20 Patienten mit gesicherter Psoriasis vulgaris in einer Hautarztpraxis in Crivitz evaluiert und einer 12-wöchigen Behandlung mit täglich 3 x 2 Kapseln Megamin forte ä 500 mg unterzogen.A total of 20 patients with confirmed psoriasis vulgaris were evaluated at a dermatological practice in Crivitz and subjected to a 12-week treatment with 3 x 2 capsules Megamin forte a 500 mg daily.
Megamin forte Kapseln enthalten 75% mikronisiertes Heulandit/Klinoptilolith mit einem Teilchendurchmesser kleiner 5 μm (EP1316530) und 25 % Brennnesselextrakt bzw. pulverisiertes Dolomit bzw. ein Gemisch dieser beiden Komponenten. Der Extrakt wurde durch Mazeration aus Blättern der Brennnessel Urtica dioica durch Extraktion mit Isopropanol bei Raumtemperatur für 24 Stunden hergestellt.Megamin forte capsules contain 75% micronized heulandite / clinoptilolite with a particle diameter of less than 5 μm (EP1316530) and 25% nettle extract or powdered dolomite or a mixture of these two components. The extract was made by maceration from leaves of stinging nettle Urtica dioica prepared by extraction with isopropanol at room temperature for 24 hours.
Vor und am Ende der Therapie erfolgte die visuelle Beurteilung der betroffenen Hautareale, es wurde eine Fotodokumentation durchgeführt und laborchemisch wurden das CrP, das Differenzialblutbild und die Lymphozytendifferenzierung (CD3, CD4, CD8, CD16, CD19, CD56) erfasst.Before and at the end of the therapy the visual assessment of the affected areas of the skin was carried out, a photo documentation was carried out and the CrP, the differential blood picture and the lymphocyte differentiation (CD3, CD4, CD8, CD16, CD19, CD56) were recorded.
Zusammenfassend ließ sich eruieren, dass bei 19 Patienten eine sichere Verbesserung der Hautbefunde nachweisbar waren, ein Patient unterbrach die Therapie wegen Völlegefühls. Sowohl im Differenzialblutbild als auch im Immunstatus ließen sich keine signifikanten Veränderungen erkennen.In summary, it was found that in 19 patients a safe improvement of the skin findings was detectable, one patient interrupted the therapy because of feeling of fullness. There were no significant changes in both the differential blood count and the immune status.
Anwendungsbeispiel 2Application Example 2
Es wurden insgesamt 20 Patienten mit gesicherter Psoriasis vulgaris in einer Hautarztpraxis in Crivitz evaluiert und einer 12-wöchigen Behandlung mit täglich 3 x 2 Kapseln Megamin forte a 500 mg unterzogen. Gleichzeitig erfolgte 2x täglich die topische Applikation der befallenen Hautareale mit Zeolith-Puder und Zeolith-haltiger Salbe sowie 1-2x pro Woche ein Bad mit Zeolith-haltigem Badesalz.A total of 20 patients with confirmed psoriasis vulgaris were evaluated at a dermatological practice in Crivitz and subjected to a 12-week treatment with 3 x 2 Megamin forte a 500 mg capsules daily. At the same time twice daily the topical application of the affected skin areas with zeolite powder and zeolite-containing ointment and 1-2 times a week a bath with zeolite-containing bath salts.
Unter diesen Bedingungen erfolgte eine Normalisierung von bis zu 100% der betroffenen Hautareale.Under these conditions, a normalization of up to 100% of the affected skin areas.
Anwendungsbeispiel 3Application example 3
In toxikologischen Studien mit dem Zeolith Heulandit/Klinoptilolith an Mäusen und Ratten über 6 bis 12 Monate wurden keine Veränderungen beobachtet, die dem verabreichten Zeolithen zuzuschreiben waren. In toxicological studies with zeolite heulandite / clinoptilolite in mice and rats for 6 to 12 months, no changes attributable to the zeolite administered were observed.

Claims

Ansprüche: Claims:
1. Mittel zur Therapie und Prophylaxe von Hauterkrankungen umfassend Zeolithe und Brennnesselextrakt bzw. Calcium- und/oder Magnesiumsalze sowie gegebenenfalls weitere Stoffe.1. An agent for the therapy and prophylaxis of skin diseases comprising zeolites and nettle extract or calcium and / or magnesium salts and optionally other substances.
2. Mittel zur Therapie und Prophylaxe von Hauterkrankungen nach Anspruch 1 umfassend Zeolithe und Brennnesselextrakt sowie gegebenenfalls weitere Stoffe.2. Agent for the therapy and prophylaxis of skin diseases according to claim 1 comprising zeolites and nettle extract and optionally other substances.
3. Mittel zur Therapie und Prophylaxe von Hauterkrankungen nach Anspruch 1 umfassend Zeolithe und Calcium- und/oder Magnesiumsalze sowie gegebenenfalls weitere Stoffe.3. An agent for the therapy and prophylaxis of skin diseases according to claim 1 comprising zeolites and calcium and / or magnesium salts and optionally other substances.
4. Mittel nach Anspruch 1 , dadurch gekennzeichnet, dass es sich bei der Hauterkrankung um Psoriasis, Neurodermitis oder um atopische Dermatitis Akne handelt.4. Composition according to claim 1, characterized in that the skin disease is psoriasis, atopic dermatitis or atopic dermatitis acne.
5. Mittel nach Anspruch 1 - 4, dadurch gekennzeichnet, dass es sich bei Psoriasis um Psoriasis der Handflächen und Fußsohlen, um Nagel-Psoriasis, um die erythrodermatische Form der Psoriasis, um Psoriasis pustulosa bzw. um Psoriasis arthropathica handelt.5. Composition according to claim 1 - 4, characterized in that psoriasis is psoriasis of the palms and soles, nail psoriasis, the erythrodermatic form of psoriasis, psoriasis pustulosa or psoriasis arthropathica.
6. Mittel nach Anspruch 1 - 5, dadurch gekennzeichnet, dass Zeolith einer oder mehreren der folgenden Zeolitharten verwendet wird: Heulandit/Klinoptilolith, Natrolith, Thomsonit.6. Composition according to claim 1-5, characterized in that zeolite is used one or more of the following zeolite types: heulandite / clinoptilolite, natrolite, thomsonite.
7. Mittel nach Anspruch 6, dadurch gekennzeichnet, dass mikronisiertes Heulandit/Klinoptilolith mit einem Teilchendurchmesser von weniger als 5 μm verwendet wird. 7. Composition according to claim 6, characterized in that micronized heulandite / clinoptilolite having a particle diameter of less than 5 microns is used.
8. Mittel nach Anspruch 1 - 2, dadurch gekennzeichnet, dass es Extrakte aus Brennnesseln der Gattung Urtica dioica (Große Brennnessel) und/oder Urtica urens (Kleine Brennnessel) enthält.8. Composition according to claim 1 - 2, characterized in that it contains extracts of nettles of the genus Urtica dioica (Great stinging nettle) and / or Urtica urens (Small stinging nettle).
9. Mittel nach Anspruch 1 - 2, dadurch gekennzeichnet, dass die Bestandteile in folgenden Mengen enthalten sind:9. Composition according to claim 1 - 2, characterized in that the constituents are contained in the following amounts:
- Zeolith 1 - 95%- Zeolite 1 - 95%
- Brennnesselextrakt 5 - 80%- nettle extract 5 - 80%
10. Mittel nach Anspruch 9, dadurch gekennzeichnet, dass die Bestandteile in folgenden Mengen enthalten sind:10. Composition according to claim 9, characterized in that the constituents are contained in the following amounts:
- Zeolith 40 - 80%- zeolite 40 - 80%
- Brennnesselextrakt 20 - 60%- nettle extract 20 - 60%
11. Mittel nach Anspruch 9 und 10, dadurch gekennzeichnet, dass die Bestandteile in folgenden Mengen enthalten sind:11. Composition according to claim 9 and 10, characterized in that the constituents are contained in the following amounts:
- Zeolith 50 - 80%- Zeolite 50 - 80%
- Brennnesselextrakt 1 - 20%- Nettle extract 1 - 20%
12. Mittel nach Anspruch 1 und 3, dadurch gekennzeichnet, dass es sich bei den Calcium- und/oder Magnesiumsalzen um die entsprechenden Carbonate, Sulfate und/oder Chloride handelt.12. Composition according to claim 1 and 3, characterized in that it is the corresponding carbonates, sulfates and / or chlorides in the calcium and / or magnesium salts.
13. Mittel nach Anspruch 12, dadurch gekennzeichnet, dass es sich bei den Calcium- und/oder Magnesiumsalzen um Dolomit handelt.13. A composition according to claim 12, characterized in that it is dolomite in the calcium and / or magnesium salts.
14. Mittel nach Anspruch 1 und 3, dadurch gekennzeichnet, dass die Bestandteile in folgenden Mengen enthalten sind:14. Composition according to claim 1 and 3, characterized in that the constituents are contained in the following amounts:
- Zeolith 1 - 95%- Zeolite 1 - 95%
- Calcium- und/oder Magnesiumsalze 5 - 80%- calcium and / or magnesium salts 5 - 80%
15. Mittel nach Anspruch 14, dadurch gekennzeichnet, dass die Bestandteile in folgenden Mengen enthalten sind:15. Composition according to claim 14, characterized in that the constituents are contained in the following amounts:
- Zeolith 40 - 80% - Calcium- und/oder Magnesiumsalze 20 - 60%- zeolite 40 - 80% - calcium and / or magnesium salts 20 - 60%
16. Mittel nach Anspruch 14 und 15, dadurch gekennzeichnet, dass die Bestandteile in folgenden Mengen enthalten sind:16. Composition according to claim 14 and 15, characterized in that the constituents are contained in the following amounts:
- Zeolith 50 - 80%- Zeolite 50 - 80%
- Calcium- und/oder Magnesiumsalze 1 - 20%- calcium and / or magnesium salts 1 - 20%
17. Verwendung des Mittels nach Anspruch 1 - 16 in Form eines Nahrungsergänzungsmittels, gegebenenfalls in Kombination mit weiteren Stoffen.17. Use of the agent according to claim 1 - 16 in the form of a dietary supplement, optionally in combination with other substances.
18. Verwendung des Mittels nach Anspruch 17 gemeinsam mit einer oder mehreren der folgenden Stoffe: 100%iges Zeolith-Puder, Zeolith-haltige Lotionen und/oder Zeolith-haltige Badesalze.18. Use of the agent according to claim 17 together with one or more of the following substances: 100% zeolite powder, zeolite-containing lotions and / or zeolite-containing bath salts.
19. Verwendung des Mittels nach Anspruch 1 - 16 durch orale Einnahme und/oder durch topische Behandlung der Haut.19. Use of the agent according to claim 1 - 16 by oral ingestion and / or by topical treatment of the skin.
20. Verwendung des Mittels nach Anspruch 1 - 16 in Form von Pulver, Tablette, Kapsel, Creme, Milch, Gel, Emulsion, Seife, Shampoo oder in wässriger Form. 20. Use of the agent according to claim 1-16 in the form of powder, tablet, capsule, cream, milk, gel, emulsion, soap, shampoo or in aqueous form.
PCT/DE2006/000700 2005-04-15 2006-04-18 Agent for use in the therapy and prophylaxis of skin diseases WO2006108414A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102005017730 2005-04-15
DE102005017730.1 2005-04-15
DE102005020467.8 2005-04-29
DE102005020467A DE102005020467A1 (en) 2005-04-15 2005-04-29 Agent for the therapy and prophylaxis of skin diseases

Publications (2)

Publication Number Publication Date
WO2006108414A2 true WO2006108414A2 (en) 2006-10-19
WO2006108414A3 WO2006108414A3 (en) 2007-03-08

Family

ID=36951516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2006/000700 WO2006108414A2 (en) 2005-04-15 2006-04-18 Agent for use in the therapy and prophylaxis of skin diseases

Country Status (2)

Country Link
DE (1) DE102005020467A1 (en)
WO (1) WO2006108414A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149375A1 (en) 2008-07-28 2010-02-03 Despharma Kft. Compositions for the treatment of dermatological diseases, and uses thereof
AT511961B1 (en) * 2011-11-15 2013-04-15 Ipus Mineral & Umwelttechnologie Gmbh AQUEOUS PASTE FOR OUTSIDE APPLICATION TO ELEMENTS OF MILK-PRODUCING ANIMALS
WO2014086893A1 (en) 2012-12-04 2014-06-12 Purmin Gmbh Geopolymer hydrogels or suspensions and storage-stable granular mineral composites with colloidal portion, method for producing same and use thereof
WO2023220768A1 (en) * 2022-05-17 2023-11-23 Stritech Holdings Pty Ltd Acne control formulations

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3482745A1 (en) * 2017-11-08 2019-05-15 Dn 360 S.R.L. Oral controlled-release calcium compound and method for preparing it

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57134408A (en) * 1981-02-13 1982-08-19 Minato Sangyo Kk Skin activating agent
JPH06293613A (en) * 1994-02-17 1994-10-21 Hakugen:Kk Mothproofing agent for clothes
WO2002100420A2 (en) * 2001-06-08 2002-12-19 Universita' Degli Studi Di Napoli 'federico Ii' Pharmaceutical zeolite-based compositions containing zinc and erythromycin, to be used in the treatment of acne
WO2004037220A1 (en) * 2002-10-25 2004-05-06 Shiseido Company, Ltd. Skin preparations for external use
US20050031708A1 (en) * 2003-08-06 2005-02-10 Portney Micah S. Composition comprising a zeolite compound for treatment of diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6475407A (en) * 1987-09-14 1989-03-22 Soft Silica Kk Bacteriostatic agent and germination and rooting promoting agent for directly sowed paddy rice seed
JP2003092998A (en) * 2001-09-25 2003-04-02 Harumi Sangyo Kk Fodder for raising livestock

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57134408A (en) * 1981-02-13 1982-08-19 Minato Sangyo Kk Skin activating agent
JPH06293613A (en) * 1994-02-17 1994-10-21 Hakugen:Kk Mothproofing agent for clothes
WO2002100420A2 (en) * 2001-06-08 2002-12-19 Universita' Degli Studi Di Napoli 'federico Ii' Pharmaceutical zeolite-based compositions containing zinc and erythromycin, to be used in the treatment of acne
WO2004037220A1 (en) * 2002-10-25 2004-05-06 Shiseido Company, Ltd. Skin preparations for external use
US20050031708A1 (en) * 2003-08-06 2005-02-10 Portney Micah S. Composition comprising a zeolite compound for treatment of diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANZE M. ET AL.: "Development of newly formulated antimicrobial wound dressing (non woven sheet of Ag-Zn Zeolite impregnated Ca-Alginate fiber: A multi-centric clinical study" JAPANESE PHARMACOLOGY AND THERAPEUTICS, Bd. 27, Nr. 4, 1999, Seiten 215-245, XP009072325 JP *
DATABASE WPI Week 198918 Derwent Publications Ltd., London, GB; AN 1989-132529 XP002360292 "Compsn. for application to seeds before sowing in paddy field - contains clay silicate and/or (artificial) zeolite, and calcium peroxide, to accelerate germination and root generation and kill bacteria" & JP 01 075407 A (SOFT SILICA KK) 22. März 1989 (1989-03-22) *
DATABASE WPI Week 200363 Derwent Publications Ltd., London, GB; AN 2003-666418 XP002329003 "Fodder for livestock such as cows and pigs, comprises natural zeolite and materials such as silica, alumina, calcium blended with natural minerals such as zinc, magnesium and iron" & JP 2003 092998 A (HARUMI SANGYO KK) 2. April 2003 (2003-04-02) *
MIYASATO, K. ET AL.: "A newly developed wound dressing made of alginate fiber containing zeolite substituted by silver and zinc" JAPANESE PHARMACOLOGY AND THERAPEUTICS, Bd. 27, Nr. 4, 1999, Seiten 177-203, XP009072324 JP *
SVERKO V. ET AL.: "Natural Micronised Clinoptilolite Mixtures with Urtica dioica L. Extract as Possible Antioxidants" FOOD TECHNOLOGY AND BIOTECHNOLOGY, Bd. 42, Nr. 3, Juli 2004 (2004-07), Seiten 189-192, XP009072328 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149375A1 (en) 2008-07-28 2010-02-03 Despharma Kft. Compositions for the treatment of dermatological diseases, and uses thereof
JP2011529098A (en) * 2008-07-28 2011-12-01 デスファルマ エジェースシェーゲージュイ ソルガールタトー コルラートルト フェレレーシュシェーギュー タルシャシャーグ Composition for the prevention and treatment of skin / mucosal diseases and use thereof
US20150118314A1 (en) * 2008-07-28 2015-04-30 Despharma Kft. Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
JP2015096506A (en) * 2008-07-28 2015-05-21 デスファルマ エジェースシェーゲージュイ ソルガールタトー コルラートルト フェレレーシュシェーギュー タルシャシャーグＤｅｓｐｈａｒｍａ Ｅｇｅｓｚｓｅｇｕｇｙｉ Ｓｚｏｌｇａｌｔａｔｏ Ｋｏｒｌａｔｏｌｔ Ｆｅｌｅｌｏｓｓｅｇｕ Ｔａｒｓａｓａｇ Compositions for prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
AU2009275936B2 (en) * 2008-07-28 2016-02-18 Despharma Egeszegugyi Szolgaltato Korlatolt Felelossegu Tarsasag Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
AU2009275936A8 (en) * 2008-07-28 2016-02-18 Despharma Egeszegugyi Szolgaltato Korlatolt Felelossegu Tarsasag Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
EA025440B1 (en) * 2008-07-28 2016-12-30 Дешпхарма Егешжегюгьи Сольгальтато Корлатольт Фелелёшшегю Таршашаг Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
AT511961B1 (en) * 2011-11-15 2013-04-15 Ipus Mineral & Umwelttechnologie Gmbh AQUEOUS PASTE FOR OUTSIDE APPLICATION TO ELEMENTS OF MILK-PRODUCING ANIMALS
AT511961A4 (en) * 2011-11-15 2013-04-15 Ipus Mineral & Umwelttechnologie Gmbh AQUEOUS PASTE FOR OUTSIDE APPLICATION TO ELEMENTS OF MILK-PRODUCING ANIMALS
WO2014086893A1 (en) 2012-12-04 2014-06-12 Purmin Gmbh Geopolymer hydrogels or suspensions and storage-stable granular mineral composites with colloidal portion, method for producing same and use thereof
WO2023220768A1 (en) * 2022-05-17 2023-11-23 Stritech Holdings Pty Ltd Acne control formulations

Also Published As

Publication number Publication date
WO2006108414A3 (en) 2007-03-08
DE102005020467A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
EP1073445B1 (en) Substance mixture for topical application comprising olive oil and honey
DE19831798A1 (en) Microcirculation improving skin and tissue care or treatment composition, containing salts, aminoacids and peroxide, used as cosmetic, medicament or nutrient supplement
DE69825279T2 (en) USE OF GLUCOSAMINE AND GLUCOSAMINE DERIVATIVES FOR THE FAST RELIEF OF JUCKREIZ OR LOCALIZED PAIN
WO2006108414A2 (en) Agent for use in the therapy and prophylaxis of skin diseases
EP0037488B1 (en) Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes
DE2113215A1 (en) Therapeutic compound
DE102008036725A1 (en) Pharmaceutical composition for nasal administration
EP1180940A2 (en) Active agent and combination of active agents for human beings and animals
EP1628671A1 (en) Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases
EP1911464B1 (en) Gel-type base compound based on essential oil mixtures for dermal and transdermal application
DE202016106651U1 (en) Anti-inflammatory composition of cannabidiol and betulin
DE102009052808A1 (en) Ointment, useful e.g. for treating salt deficiency, acute and chronic trauma, comprises ointment base and homeopathically diluted mineral salt including e.g. calcium phosphate, iron phosphate, potassium chloride and potassium phosphate
DE102005021382A1 (en) Agent, useful to treat and prevent skin diseases e.g. psoriasis, preferably psoriasis of the palms and foot, nail psoriasis, neurodermatitis and atopic dermatitis, comprises zeolite, stinging nettle extract and further materials
EP3299026A1 (en) Extracts made from seeds of aframomum species and their use
WO2006122541A2 (en) Pharmaceutically effective composition for treating diabetes
EP0256353A2 (en) Pharmaceutical therapy against the bad absorption of food or oral drugs
EP0265662A2 (en) Pharmaceutic composition
DE202006018518U1 (en) Skin care product, useful for e.g. caring dry-, allergic- and wounded skin and skin damaged by cancer therapy, comprises sea-buckthorn fruit pulp oil, shea nut butter, jojoba oil, vitamin E acetate and fatty vegetable oil e.g. almond oil
LU501504B1 (en) POWDERED FOOD SUPPLEMENT FOR MAKING A BEVERAGE
DE19910697C2 (en) Process for the preparation of a therapeutically active substance and use thereof
DE20320103U1 (en) Composition for topical treatment of skin, useful for treating e.g. eczema and pruritus, comprises a fatty alcohol and three specific plant extracts
DD297332A5 (en) NEW ORAL DRUG PREPARATION TO IMPROVE AVAILABILITY
DE102004034747B4 (en) Ointment preparation suitable for neurodermitic skin diseases
DE202023102783U1 (en) Composition of an antibacterial lotion with lemongrass oil enriched with bioactive substances
EP1430891A1 (en) Oil-acid-emulsion for the treatment of joint diseases and for the stimulation of blood-circulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06722818

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6722818

Country of ref document: EP